MX2023003842A - Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2. - Google Patents
Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2.Info
- Publication number
- MX2023003842A MX2023003842A MX2023003842A MX2023003842A MX2023003842A MX 2023003842 A MX2023003842 A MX 2023003842A MX 2023003842 A MX2023003842 A MX 2023003842A MX 2023003842 A MX2023003842 A MX 2023003842A MX 2023003842 A MX2023003842 A MX 2023003842A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- compounds
- inhibitors
- diacylglyceride
- acyltransferase
- Prior art date
Links
- 150000008641 benzimidazolones Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 229940127194 DGAT2 inhibitor Drugs 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 230000006999 cognitive decline Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se inventan compuestos de Fórmula I (ver Fórmula) y sales farmacéuticamente aceptables, ésteres y profármacos de los mismos, que son inhibidores de DGAT2. También se proporcionan métodos de preparación de compuestos de Fórmula I, composiciones farmacéuticas que comprenden compuestos de Fórmula I y métodos de uso de estos compuestos para tratar la esteatosis hepática, esteatohepatitis no alcohólica (EHNA), fibrosis, diabetes mellitus de tipo 2, obesidad, hiperlipidemia, hipercolesterolemia, ateroesclerosis, declive cognitivo, demencia, enfermedades cardiorrenales tales como enfermedades renales crónicas e insuficiencia cardíaca y enfermedades y afecciones relacionadas, que comprenden administrar un compuesto de Fórmula I a un paciente que lo necesita.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089068P | 2020-10-08 | 2020-10-08 | |
| PCT/US2021/053680 WO2022076495A1 (en) | 2020-10-08 | 2021-10-06 | Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003842A true MX2023003842A (es) | 2023-04-14 |
Family
ID=78500729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003842A MX2023003842A (es) | 2020-10-08 | 2021-10-06 | Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11976061B2 (es) |
| EP (1) | EP4225739A1 (es) |
| JP (1) | JP2023545741A (es) |
| KR (1) | KR20230084258A (es) |
| CN (1) | CN116685577A (es) |
| AR (1) | AR123700A1 (es) |
| AU (1) | AU2021356589A1 (es) |
| CA (1) | CA3195014A1 (es) |
| CL (1) | CL2023000997A1 (es) |
| CO (1) | CO2023004365A2 (es) |
| CR (1) | CR20230159A (es) |
| DO (1) | DOP2023000069A (es) |
| EC (1) | ECSP23033936A (es) |
| IL (1) | IL301791A (es) |
| MX (1) | MX2023003842A (es) |
| PE (1) | PE20240216A1 (es) |
| TW (1) | TW202229243A (es) |
| WO (1) | WO2022076495A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024118858A1 (en) | 2022-12-02 | 2024-06-06 | Merck Sharp & Dohme Llc | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US162818A (en) | 1875-05-04 | Improvement in brick-kilns | ||
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| JP2001515482A (ja) | 1997-03-07 | 2001-09-18 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−１，６−ビスホスファターゼの新規なベンズイミダゾールインヒビター |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| CN1215076C (zh) | 1998-09-09 | 2005-08-17 | 症变治疗公司 | 新的果糖1,6－二磷酸酶的杂芳族抑制剂 |
| WO2003053363A2 (en) | 2001-12-19 | 2003-07-03 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
| EP2170883A1 (en) | 2007-06-28 | 2010-04-07 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| PE20142164A1 (es) | 2012-04-06 | 2014-12-27 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| AR098394A1 (es) | 2013-11-25 | 2016-05-26 | Lilly Co Eli | Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2) |
| AP2016009407A0 (en) | 2014-03-17 | 2016-08-31 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
| WO2016036638A1 (en) | 2014-09-05 | 2016-03-10 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| EP3188732B1 (en) | 2014-09-05 | 2019-07-24 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| EP3188730B1 (en) | 2014-09-05 | 2019-05-01 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| SG10202006563PA (en) | 2015-07-10 | 2020-08-28 | Ionis Pharmaceuticals Inc | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| JP2020502058A (ja) | 2016-11-18 | 2020-01-23 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ジアシルグリセリドｏ−アシルトランスフェラーゼ２の阻害薬として有用なインダゾール誘導体 |
| RU2019117958A (ru) | 2016-11-18 | 2020-12-18 | Мерк Шарп И Доум Корп. | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
-
2021
- 2021-10-06 AR ARP210102766A patent/AR123700A1/es unknown
- 2021-10-06 US US17/494,906 patent/US11976061B2/en active Active
- 2021-10-06 AU AU2021356589A patent/AU2021356589A1/en active Pending
- 2021-10-06 CA CA3195014A patent/CA3195014A1/en active Pending
- 2021-10-06 WO PCT/US2021/053680 patent/WO2022076495A1/en active Application Filing
- 2021-10-06 JP JP2023521375A patent/JP2023545741A/ja active Pending
- 2021-10-06 IL IL301791A patent/IL301791A/en unknown
- 2021-10-06 EP EP21802077.4A patent/EP4225739A1/en active Pending
- 2021-10-06 CN CN202180082235.8A patent/CN116685577A/zh active Pending
- 2021-10-06 MX MX2023003842A patent/MX2023003842A/es unknown
- 2021-10-06 TW TW110137150A patent/TW202229243A/zh unknown
- 2021-10-06 KR KR1020237015525A patent/KR20230084258A/ko unknown
- 2021-10-06 CR CR20230159A patent/CR20230159A/es unknown
- 2021-10-06 PE PE2023001361A patent/PE20240216A1/es unknown
-
2023
- 2023-04-05 CO CONC2023/0004365A patent/CO2023004365A2/es unknown
- 2023-04-05 DO DO2023000069A patent/DOP2023000069A/es unknown
- 2023-04-05 CL CL2023000997A patent/CL2023000997A1/es unknown
- 2023-05-08 EC ECSENADI202333936A patent/ECSP23033936A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11976061B2 (en) | 2024-05-07 |
| EP4225739A1 (en) | 2023-08-16 |
| AR123700A1 (es) | 2023-01-04 |
| CR20230159A (es) | 2023-06-02 |
| CO2023004365A2 (es) | 2023-04-17 |
| CL2023000997A1 (es) | 2023-10-06 |
| DOP2023000069A (es) | 2023-05-15 |
| JP2023545741A (ja) | 2023-10-31 |
| PE20240216A1 (es) | 2024-02-16 |
| AU2021356589A1 (en) | 2023-05-25 |
| KR20230084258A (ko) | 2023-06-12 |
| WO2022076495A1 (en) | 2022-04-14 |
| CA3195014A1 (en) | 2022-04-14 |
| TW202229243A (zh) | 2022-08-01 |
| US20220112182A1 (en) | 2022-04-14 |
| CN116685577A (zh) | 2023-09-01 |
| IL301791A (en) | 2023-05-01 |
| ECSP23033936A (es) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003844A (es) | Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2. | |
| MX2019005679A (es) | Derivados de indol de utilidad como inhibidores de diacilglicerido o-aciltransferasa 2. | |
| MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
| MX2019005786A (es) | Derivados de indazol utiles como inhibidores de diacilglicerido o-aciltransferasa 2. | |
| JP6118340B2 (ja) | １１−β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤としての環状アミド誘導体およびその使用 | |
| NZ601526A (en) | Inhibitors of diacylglycerol acyl transferase | |
| MX2009000871A (es) | Novedosos inhibidores de transcriptasa inversa de vih. | |
| MX2023003842A (es) | Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2. | |
| MX2023007626A (es) | Preparacion de derivados de tetrahidroindazol como innovadores inhibidores de la diacilglicerido o-aciltransferasa 2. | |
| AU2017361253A1 (en) | MAGL inhibitors | |
| ES2829286T3 (es) | Derivado de amina cíclica y utilización farmacéutica del mismo | |
| WO2008029217A3 (en) | Dipeptidyl peptidase iv inhibitors | |
| MX2020011225A (es) | Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos. | |
| WO2011125836A1 (ja) | 線維筋痛症の治療剤又は予防剤 | |
| AU2007341218B2 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| HK1141019A1 (en) | Carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound | |
| WO2009062883A1 (en) | Drug active in neuropathic pain | |
| US4496578A (en) | Antihypertensive sulfur-containing compounds | |
| CA3233328A1 (en) | Lpxc inhibitors and uses thereof | |
| WO2011136318A1 (ja) | アルツハイマー病の治療剤又は予防剤 | |
| EP2668159A1 (en) | 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives | |
| KR101902002B1 (ko) | Cetp 억제제로서의 옥사졸리딘온 유도체 화합물 | |
| US20130165494A1 (en) | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | |
| JP2012246282A (ja) | 新規２−フェニルプロピオン酸誘導体 |